Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Drops By 71.4%

Indaptus Therapeutics, Inc. (NASDAQ:INDP) saw a large decline in short interest during the month of May. As of May 29th, there was short interest totaling 17,200 shares, a decline of 71.4% from the May 14th total of 60,118 shares. Based on an average daily volume of 132,680 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Indaptus Therapeutics Stock Performance

Shares of NASDAQ INDP traded up $0.01 during trading on Friday, reaching $3.58. The stock had a trading volume of 587,061 shares, compared to its average volume of 2,875,104. The stock has a market cap of $405.40 million, a PE ratio of -0.23 and a beta of 1.25. Indaptus Therapeutics has a one year low of $0.92 and a one year high of $19.91. The firm’s 50 day moving average price is $2.27 and its two-hundred day moving average price is $2.23.

Indaptus Therapeutics (NASDAQ:INDP) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($1.87) by $1.64.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new stake in Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 1.72% of Indaptus Therapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 7.06% of the company’s stock.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.